Skip to content

Francesco Bavato

8 papers in the library · 42 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Differential alterations in peripheral tryptophan pathways in methamphetamine versus MDMA users are linked to their contrasting psychiatric symptoms.

Translational Psychiatry May 21, 2026 Francesco Bavato, Andrea E. Steuer, Anna M. Jacobsen et al.

Methamphetamine (METH, "Crystal Meth") and 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are two types of substituted amphetamines that share structural-chemical similarities but exhibit contrasting acute and chronic effects including addictive liability. Tryptophan (TRY) pathways are involved in pleiotropic physiological functions at the interface of brain-body connections. Preclinical...

Ketamine-dependent patients with persistent psychosis have higher neurofilament light chain levels than patients with schizophrenia.

Asian Journal of Psychiatry October 1, 2024 An-Nie Chung, Ming-Chyi Huang, Tung-Hsia Liu et al. 5 citations

Ketamine can induce persisting psychosis in a subset of individuals who use it chronically and heavily. Previously, we found that the psychopathology and cognitive impairments in patients with ketamine dependence (KD) exhibiting persistent psychosis (KPP) bear resemblances with schizophrenia, albeit with less severity in those with no persistent psychosis (KNP). Furthermore, we also showed that...

DOI: 10.1016/j.ajp.2024.104167 (opens in new tab) Full text (opens in new tab) Ketamine dependence Ketamine psychosis Neurofilament light chain Persistent psychosis +4

[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].

Der Nervenarzt September 1, 2024 Johannes Jungwirth, Francesco Bavato, Boris B. Quednow 6 citations

With the discovery of the antidepressive effects of ketamine and the increasing withdrawal of the pharmaceutical industry from the development of new psychotropic drugs, the psychiatric research into the clinical application of hallucinogens in psychiatry has literally blossomed in the last two decades. Promising results for various treatment approaches with psychedelic agents, such lysergic...

DOI: 10.1007/s00115-024-01727-0 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Clinical safety Addictive potential +5

Paradoxical pharmacological dissociations result from drugs that enhance delta oscillations but preserve consciousness

Communications Biology June 20, 2023 Joel Frohlich, Pedro A. M. Mediano, Francesco Bavato et al. 16 citations

Abstract Low-frequency (<4 Hz) neural activity, particularly in the delta band, is generally indicative of loss of consciousness and cortical down states, particularly when it is diffuse and high amplitude. Remarkably, however, drug challenge studies of several diverse classes of pharmacological agents—including drugs which treat epilepsy, activate GABA B receptors, block acetylcholine...

DOI: 10.1038/s42003-023-04988-8 (opens in new tab) Full text (opens in new tab) Consciousness Cognitive psychology Delta Persistent vegetative state +1

Chronic 3,4-Methylenedioxymethamphetamine (MDMA) Use Is Related to Glutamate and GABA Concentrations in the Striatum But Not the Anterior Cingulate Cortex.

The International Journal of Neuropsychopharmacology June 1, 2023 Josua Zimmermann, Niklaus Zölch, Rebecca C Coray et al.

Background: 3,4-Methylenedioxymethamphetamine (MDMA) is a widely used recreational substance inducing acute release of serotonin. Previous studies in chronic MDMA users demonstrated selective adaptations in the serotonin system, which were assumed to be associated with cognitive deficits. However, serotonin functions are strongly entangled with glutamate as well as γ-aminobutyric acid (GABA)...

Down but not out: drugs that enhance delta oscillations but preserve consciousness

January 30, 2023 Joel Frohlich, Pedro A. M. Mediano, Francesco Bavato et al. 1 citation preprint

Delta (1 – 4 Hz) EEG/MEG activity is generally indicative of loss of consciousness and cortical down states, particularly when it is diffuse and high amplitude. Remarkably, however, drug challenge studies of several diverse classes of pharmacological agents—including antiepileptics, GABA-B-ergics, anticholinergics, and psychedelic tryptamines—demonstrate that participants appear to be...

White matter alterations in chronic MDMA use: Evidence from diffusion tensor imaging and neurofilament light chain blood levels

NeuroImage: Clinical September 19, 2022 Josua Zimmermann, Nicole Friedli, Francesco Bavato et al. 14 citations

3,4–Methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a serotonin- and noradrenaline-releasing substance, currently among the most widely used illicit substances worldwide. In animal studies, repeated exposure to MDMA has been associated with dendritic but also axonal degeneration in the brain. However, translation of the axonal findings, specifically, to humans has been repeatedly questioned...

DOI: 10.1016/j.nicl.2022.103191 (opens in new tab) Full text (opens in new tab) MDMA Neurotoxicity Axonal neuropathology White matter +2

Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (“Ecstasy”) induced cytoskeletal damage

Journal of Neural Transmission June 1, 2022 Francesco Bavato, Serena Stamatakos, C. M. Yde Ohki et al.

Abstract3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) use has been linked to persistent alterations of the brain serotonergic (5-HT) system in animal and human studies, but the molecular underpinnings are still unclear. Cytoskeletal structures such as neurofilament light chain (NfL) are promising markers of drug-induced brain toxicity and may be involved in MDMA neurotoxicity. The...